Tracy has made over 1 trades of the Esperion Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 4,345 units of ESPR stock worth $7,604 on 23 March 2018.
The largest trade she's ever made was selling 4,345 units of Esperion Therapeutics stock on 23 March 2018 worth over $7,604. On average, Tracy trades about 362 units every 0 days since 2015. As of 23 March 2018 she still owns at least 215,755 units of Esperion Therapeutics stock.
You can see the complete history of Ms. Woody stock trades at the bottom of the page.
Tracy M. Woody serves as Independent Director of the Company. Ms. Woody currently leads TMW Consulting where she works with both early-stage companies to provide initial commercial input, and companies in Phase 3 to develop and guide successful launch plans. Ms. Woody previously served as Chief Commercial Officer of Versartis, Inc. from 2017 to 2018 and KemPharm, Inc. from 2015 to 2016. Prior to KemPharm, Ms. Woody was Vice President of Sales and Marketing of NextWave Pharmaceuticals (acquired by Pfizer), and Vice President of Business Development and Vice President of Sales and Marketing at Greer Laboratories. Ms. Woody has over 20 years of commercial experience in pharmaceuticals, biologics, and medical devices, across a wide range of therapeutic areas in diverse markets. Ms. Woody also has experience with multi-billion dollar revenue brands as well as products in the rare disease space. Ms. Woody holds a Bachelor's degree in Health Promotion and Applied Physiology from East Carolina University.
As the Independent Director of Esperion Therapeutics, the total compensation of Tracy Woody at Esperion Therapeutics is $513,360. There are 3 executives at Esperion Therapeutics getting paid more, with Timothy Mayleben having the highest compensation of $1,080,850.
Tracy Woody is 50, she's been the Independent Director of Esperion Therapeutics since 2019. There are 9 older and 6 younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics Inc. is Antonio Gotto, 84, who is the Independent Director.
Tracy's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48187.
Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio... oraz Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Esperion Therapeutics executives and other stock owners filed with the SEC include: